MDW blood test to predict complications and survival after hip fracture
The Role of Monocyte Distribution Width (MDW) and Other Inflammatory Biomarkers in the Prediction of Mortality and Morbidity in Patients With Hip Fracture
National and Kapodistrian University of Athens · NCT07350785
This will test whether a routine blood measure called Monocyte Distribution Width (MDW) can help predict complications or death in people aged 65 and older who have a low-energy hip fracture.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 65 Years and up |
| Sex | All |
| Sponsor | National and Kapodistrian University of Athens (other) |
| Locations | 1 site (Kifissia, Attica) |
| Trial ID | NCT07350785 on ClinicalTrials.gov |
What this trial studies
This observational study will enroll about 100 patients aged 65 and older admitted with low-energy hip fractures at the General Hospital of Attica KAT in Kifissia. MDW, measured as part of a routine complete blood count, will be collected at hospital admission, after surgery, and at additional timepoints during the hospital stay alongside other inflammatory biomarkers. Researchers will compare MDW values to postoperative outcomes including infections, sepsis, other complications, length of stay, and mortality to see if higher MDW predicts worse outcomes. Statistical models will adjust for clinical factors to determine whether MDW adds prognostic value beyond standard tests.
Who should consider this trial
Good fit: Ideal candidates are people aged 65 or older admitted to the General Hospital of Attica KAT with a low-energy femoral neck, intertrochanteric, or subtrochanteric hip fracture and available baseline blood tests including MDW.
Not a fit: Patients under 65, those with high-energy or pathological hip fractures, or patients treated outside the enrolling hospital are unlikely to benefit from this specific program.
Why it matters
Potential benefit: If successful, MDW could help clinicians identify older hip fracture patients at higher risk for infection or death so they can provide closer monitoring or earlier treatment.
How similar studies have performed: MDW has shown promise in other settings for early detection of infection and sepsis, but its specific use to predict postoperative outcomes after hip fracture is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged ≥65 years * Admission with low-energy hip fracture (femoral neck, intertrochanteric, or subtrochanteric fracture) * Admission to General Hospital of Attica KAT * Availability of baseline laboratory measurements, including complete blood count with monocyte distribution width (MDW) and inflammatory biomarkers Exclusion Criteria: * Age \<65 years * High-energy trauma-related hip fractures * Pathological fractures
Where this trial is running
Kifissia, Attica
- Laboratory for Research of the Musculoskeletal System — Kifissia, Attica, Greece (RECRUITING)
Study contacts
- Study coordinator: Efstathios Chronopoulos
- Email: stathi24@yahoo.gr
- Phone: 00306944837793
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Sepsis, Osteoporotic Hip Fracture, Hip Fracture, Monocyte Distribution Width, Geriatric Patients, Inflammatory Biomarkers, Postoperative Mortality, Postoperative Morbidity